Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload

Hepatology

Volumn 51, Issue 4, 2010, Pages 1119-1121

  Fargion, Silvia ^a   Valenti, Luca ^a   Fracanzani, Anna Ludovica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CHELATING AGENT; MEMBRANE PROTEIN; PROTEIN P53; SUPEROXIDE DISMUTASE; TUMOR MARKER;

ALCOHOL ABUSE; BLOOD DONOR; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL DEATH; CLINICAL ASSESSMENT; DNA DAMAGE; EDITORIAL; GENE MUTATION; GENETIC DISORDER; HEMOCHROMATOSIS; HEREDITY; HUMAN; INFLAMMATION; IRON METABOLISM; IRON OVERLOAD; LIVER CANCER; MUTAGENESIS; ONCOGENE; PHLEBOTOMY; PRIORITY JOURNAL;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON OVERLOAD; MEMBRANE PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 77950599661     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23541     Document Type: Editorial

References (18)

1. Edgren G, Nyren O, Melbye M. Cancer as a ferrotoxic disease: are we getting hard stainless evidence? J Natl Cancer Inst 2008;100: 976-977.
2. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chela-tors with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006;103: 14901-14906.
3. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982-1994.
4. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. HEPATOLOGY 2001;33:647-651. (Pubitemid 32185227)
5. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-1741. (Pubitemid 37500438)
6. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
7. Edgren G, Reilly M, Hjalgrim H, Tran TN, Rostgaard K, Adami J, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008;100:572-579.
8. Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, et al. Evidence for an association between compound heterozygos-ity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1460-1463.
9. Syrjakoski K, Fredriksson H, Ikonen T, Kuukasjarvi T, Autio V, Matikai-nen MP, et al. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients. Int J Cancer 2006;118:518-520.
10. Shi Z, Johnstone D, Talseth-Palmer BA, Evans TJ, Spigelman AD, Groombridge C, et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 2009;125:78-83.
11. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-4588.
12. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Ange-lucci E, Van Lint MT, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelo-dysplastic syndrome undergoing allogeneic stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2009; doi:10.3324/haematol.2009.011429.
13. Osborne NJ, Gurrin LC, Allen KJ, Costantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increaed risk of breast and colorectal cancer. HEPATOLOGY 2010;51:1311-1318.
14. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemo-chromatosis. N Engl J Med 2008;358:221-230.
15. Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gas-troenterology 2008;135:1945-1952.
16. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007;60:1-7.
17. Dongiovanni P, Fracanzani A, Cairo G, Megazzini CP, Gatti S, Rametta R, et al. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010;176:1006-1017.
18. Valenti L, Conte D, Piperno A, Dongiovanni P, Fracanzani AL, Fra-quelli M, et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 2004;41:946-950.